Trial
NCT01268059
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
MedImmune LLC
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
Carboplatin
Why stopped
In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-23